Comparison of Clinicopathologic Features and Outcomes Between Synchronous and Metachronous Bilateral Breast Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Bilateral breast cancer (BBC) can be divided into two concurrent lesions, depending on the time of occurrence of primary cancer and secondary tumors after treatment of the primary cancer. This study aimed to compare the clinicopathological characteristics and results of synchronous BBC (SBBC) and metachronous BBC (MBBC).Methods: Data of patients diagnosed with breast cancer at Wonkwang university Hospital between October 1991 and October 2021 were retrospectively reviewed. Data of 3,259 patients who were diagnosed with malignant neoplasm of the right or left breast were reviewed. The tumor was defined as SBBC when another cancer was identified as BBC simultaneously or within six months after the primary breast cancer, and as MBBC when another cancer was identified after six months. Among patients with BBC, 31 had SBBC and 32 had MBBC.Results: In SBBC patients, the median age was 59.9 years, and the condition was diagnosed 3.3 years later compared with MBBC. The primary and secondary tumors of SBBC had lower disease stage, even when diagnosed late. Except for tumor, node, and metastasis stage, MBBC showed more invasive ductal carcinoma, while SBBC showed relatively more ductal carcinoma <i>in situ</i> in both primary and secondary tumors compared with MBBC. In addition, SBBC showed lower hormone receptor positivity rates and Ki-67 levels compared with MBBC. MBBC patients showed a higher survival rate compared with SBBC patients. MBBC is associated with higher overall survival rate compared with SBBC, and its prognosis is not worse compared with that of unilateral breast cancer. In the case of secondary tumor that develops in the contralateral breast without evidence of metastasis, the survival rate is similar to that of unilateral breast cancer, while the treatment is similar to that of primary tumor.Conclusion: As those with SBBC have a worse survival, these patients will require more medical attention; meanwhile, MBBC requires an active treatment approach that is equivalent to that for unilateral breast cancer.
Abstract
Purpose: Bilateral breast cancer (BBC) can be divided into two concurrent lesions, depending on the time of occurrence of primary cancer and secondary tumors after treatment of the primary cancer. This study aimed to compare the clinicopathological characteristics and results of synchronous BBC (SBBC) and metachronous BBC (MBBC).Methods: Data of patients diagnosed with breast cancer at Wonkwang university Hospital between October 1991 and October 2021 were retrospectively reviewed. Data of 3,259 patients who were diagnosed with malignant neoplasm of the right or left breast were reviewed. The tumor was defined as SBBC when another cancer was identified as BBC simultaneously or within six months after the primary breast cancer, and as MBBC when another cancer was identified after six months. Among patients with BBC, 31 had SBBC and 32 had MBBC.Results: In SBBC patients, the median age was 59.9 years, and the condition was diagnosed 3.3 years later compared with MBBC. The primary and secondary tumors of SBBC had lower disease stage, even when diagnosed late. Except for tumor, node, and metastasis stage, MBBC showed more invasive ductal carcinoma, while SBBC showed relatively more ductal carcinoma <i>in situ</i> in both primary and secondary tumors compared with MBBC. In addition, SBBC showed lower hormone receptor positivity rates and Ki-67 levels compared with MBBC. MBBC patients showed a higher survival rate compared with SBBC patients. MBBC is associated with higher overall survival rate compared with SBBC, and its prognosis is not worse compared with that of unilateral breast cancer. In the case of secondary tumor that develops in the contralateral breast without evidence of metastasis, the survival rate is similar to that of unilateral breast cancer, while the treatment is similar to that of primary tumor.Conclusion: As those with SBBC have a worse survival, these patients will require more medical attention; meanwhile, MBBC requires an active treatment approach that is equivalent to that for unilateral breast cancer.
참고문헌 (26)
- Annual report of cancer statistics in Korea in 2018, "Korea Central Cancer Registry", Ministry of Health and Welfare, ~ (2020)
- Dixon JM, "Infiltrating lobular carcinoma of the breast : an evaluation of the incidence and consequence of bilateral disease", Br J Surg, 70, pp.513~516 (1983)
- Fisher ER, "Pathologic findings from the national surgical adjuvant breast project : XI. Bilateral breast cancer", Cancer, 54, pp.3002~3011 (1984)
- Hislop TG, "Second primary cancers of the breast : incidence and risk factors", Br J Cancer, 49, pp.79~85 (1984)
- Horn PL, "Risk of contralateral breast cancer. Associations with histologic, clinical, and therapeutic factors", Cancer, 62, pp.412~424 (1988)
- Karakas Y, "Comparison of prognosis and clinical features between synchronous bilateral and unilateral breast cancers", J BUON, 22, pp.623~627 (2017)
- Shi YX, "Comparison of clinicopathological characteristics and prognoses between bilateral and unilateral breast cancer", J Cancer Res Clin Oncol, 138, pp.705~714 (2012)
- Soliman NA, "Ki-67 as a prognostic marker according to breast cancer molecular subtype", Cancer Biol Med, 13, pp.496~504 (2016)
- Lee CH, "Clinical characteristics of metachronous contralateral breast cancer following diagnosis interval", Korean J Clin Oncol, 11, pp.43~50 (2015)
- Bland KI, "The breast: comprehensive management of benign and malignant diseases", pp.967.e2~973.e2 (2018), Elsevier
- Kilgore AR, "The incidence of cancer in the second breast : after radical removal of one breast for cancer", J Am Med Assoc, 77, pp.454~457 (1921)
- Bernstein JL, "Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer", Am J Epidemiol, 136, pp.925~936 (1992)
- Rhiem K, "The risk of contralateral breast cancer in patients from BRCA1", 2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families : a retrospective cohort study, 2012, pp.14, R156~
- Jeon MH, "Clinical review of bilateral breast cancer", J Breast Cancer, 8, pp.128~133 (2005)
- Hammond ME, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, 2010, pp.28, 2784~2795
- Wolff AC, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, 2007, pp.25, 118~145
- Sandberg ME, "Estrogen receptor status in relation to risk of contralateral breast cancer—A population-based cohort study", PLoS One, 7, pp.e46535~ (2012)
- Abo-Madyan Y, "Second cancer risk after 3D-CRT, IMRT and VMAT for breast cancer", Radiother Oncol, 110, pp.471~476 (2014)
- Mezencev R, "Hormone receptor status of contralateral breast cancers : analysis of data from the US SEER population-based registries", Breast Cancer, 24, pp.400~410 (2017)
- Jobsen JJ, "Synchronous bilateral breast cancer : prognostic value and incidence", Breast, 12, pp.83~88 (2003)
- Jobsen JJ, "Bilateral breast cancer, synchronous and metachronous; differences and outcome", Breast Cancer Res Treat, 153, pp.277~283 (2015)
- Kheirelseid EA, "Bilateral breast cancer : analysis of incidence, outcome, survival and disease characteristics", Breast Cancer Res Treat, 126, pp.131~140 (2011)
- Holm M, "Prognosis of synchronous bilateral breast cancer : a review and meta-analysis of observational studies", Breast Cancer Res Treat, 146, pp.461~475 (2014)
- Vichapat V, "Tumor stage affects risk and prognosis of contralateral breast cancer : results from a large Swedish-population-based study", J Clin Oncol, 30, pp.3478~3485 (2012)
- Beckmann KR, "Clinical characteristics and outcomes of bilateral breast cancer in an Australian cohort", Breast, 20, pp.158~164 (2011)
- Shen K, "Worse characteristics can predict survival effectively in bilateral primary breast cancer : a competing risk nomogram using the SEER database", Cancer Med, 8, pp.7890~7902 (2019)